Advaxis (NASDAQ: ADXS) shares advanced on Monday after the immunotherapist printed upbeat data from a recent study involving canine osteosarcoma.
The company announced that data from a dose-escalation study of ADXS-HER2 in canine osteosarcoma was published online on March 18 in Clinical Cancer Research, a journal of the American Association for Cancer Research.
HER2 is expressed in roughly 40% to 60% of pediatric and canine osteosarcomas and in pulmonary metastatic disease, providing strong rationale for HER2 targeted immunotherapy in these cancers.
This treatment with ADXS-HER2 reduced the incidence of metastatic disease and prolonged survival relative to a historical control group. The median survival time for the ADXS-HER2 treated dogs was 956 days, which was significantly longer than the 423 day median survival time of the historical control group.
Osteosarcoma is the most common primary bone tumor in dogs, with over 10,000 dogs diagnosed annually. Osteosarcoma is also the most common bone cancer in children and teenagers.
Advaxis shares closed up 12.3% at $9.25.